Straits Times Index
3,295.81 +5.11 (+0.16%) Nikkei
38,221.28 -7.83 (-0.02%) Hang Seng
19,036.59 +72.91 (+0.38%) FTSE 100
8,433.76 +261.61 (+3.20%) Bitcoin USD
61,078.03 +149.98 (+0.25%) CMC Crypto 200
1,254.86 -57.77 (-4.40%)
AB Science S.A. (0Q77.L)
| Previous close | 2.0300 |
| Open | 0.0000 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.0000 - 0.0000 |
| 52-week range | |
| Volume | |
| Avg. volume | 5,479 |
| Market cap | 814,948 |
| Beta (5Y monthly) | 1.10 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
AB Science : A new publication in the medical journal Muscle & Nerve validates the use of the rate of decline of ALSFR-S score (ΔFS) for the design of clinical studies and the treatment choice for amyotrophic lateral sclerosis (ALS) patient
PRESS RELEASE A NEW PUBLICATION IN THE MEDICAL JOURNAL MUSCLE & NERVE VALIDATES THE USE OF THE RATE OF DECLINE OF ALSFRS-R SCORE (ΔFS) FOR THE DESIGN OF CLINICAL STUDIES AND THE TREATMENT CHOICE FOR AMYOTROPHIC LATERAL SCLEROSIS (ALS) PATIENTS THIS PUBLICATION VALIDATES THE CLINICAL TRIAL DESIGN OF MASITINIB PHASE 2/3 STUDY AB10015 AND CONFIRMATORY STUDY IN ALS Paris, May 07, 2024, 6pm CET AB Science SA (Euronext - FR0010557264 - AB) today announced the publication of an article in Muscle & Nerv
- GlobeNewswire
AB Science : The Paris Court of Appeal confirms the acquittal of the CEO of AB Science, Alain Moussy, and reduces the amount of the financial penalty imposed on AB Science
PRESS RELEASE THE PARIS COURT OF APPEAL CONFIRMS THE ACQUITTAL OF THE CEO OF AB SCIENCE, ALAIN MOUSSY, AND REDUCES THE AMOUNT OF THE FINANCIAL PENALTY IMPOSED ON AB SCIENCE Paris, May 2, 2024, 7pm CET AB Science SA (Euronext - FR0010557264 - AB) and the Chairman of the French market regulator (Autorité des Marchés Financiers - AMF) had filed an appeal to the Paris Court of Appeal against the decision of the AMF Sanctions commission, dated March 24, 2022, which acquitted Alain Moussy, CEO of AB S
- GlobeNewswire
AB Science announces a slight delay in the publication of its 2023 annual financial report
PRESS RELEASE AB SCIENCE ANNOUNCES A SLIGHT DELAY IN THE PUBLICATION OF ITS 2023 ANNUAL FINANCIAL REPORT THE COMPANY WILL PUBLISH ITS 2023 ANNUAL FINANCIAL REPORT NO LATER THAN 15 MAY 2024 Paris, April 30 2024, 6.30pm CET AB Science SA (Euronext - FR0010557264 - AB) today announced that it has postponed the publication of its 2023 annual financial report, initially scheduled for 30 April 2024, to give the auditors time to complete their audit work. The Company will publish its 2023 annual financ
